Precision radiation may boost stem cell transplant success in tough leukemias

NCT ID NCT02094794

First seen Jul 01, 2026 · Last updated Jul 02, 2026 · Updated 1 time

Summary

This study tests a precise radiation method called total marrow and lymphoid irradiation (TMLI) given with two chemotherapy drugs (etoposide and cyclophosphamide) before a donor stem cell transplant. The goal is to safely deliver higher radiation doses to the bone marrow to wipe out cancer cells while protecting nearby organs. The trial enrolls adults with high-risk acute lymphocytic or myeloid leukemia that has not responded to previous treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
total marrow and lymphoid irradiation (TMLI), cyclophosphamide, etoposide
What this could lead to
If successful, this approach could improve outcomes for patients with hard-to-treat leukemia by delivering higher radiation doses to the bone marrow while reducing side effects.
What could go wrong
This is a phase 2 trial, so results are still preliminary. The combination may still cause serious side effects, and it is not yet proven to be better than standard treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • City of Hope Medical Center

    Duarte, California, 91010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.